Physician profile
Timothy B Mclaughlin
NPI 1407839194
$9,023.18
in general payments reported to CMS, 2019-2025
30 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,613 · 2020: $782 · 2021: $1,286 · 2022: $695 · 2023: $818 · 2024: $1,162 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,647.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,652.41 | 2019-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Allergan, INC. | $1,115.98 | 2019-2022 | |
| Abbvie INC. | $1,012.58 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $681.75 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $516.96 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $386.69 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Aerie Pharmaceuticals, INC. | $350.83 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $293.43 | 2019-2025 | Tecnis Simplicity |
| Glaukos Corporation | $254.04 | 2019-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Novartis Pharmaceuticals Corporation | $231.02 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $173.09 | 2021-2025 | Acthar |
| Sight Sciences, INC. | $163.40 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $157.82 | 2019-2022 | |
| Amgen INC. | $157.16 | 2024-2025 | Uplizna, Tepezza |
| Tarsus Pharmaceuticals, INC. | $155.36 | 2025 | Xdemvy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $146.64 | 2021-2025 | Oxervate |
| New World Medical,INC. | $136.60 | 2021-2025 | Via360, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Harrow Eye, LLC | $70.23 | 2024-2025 | Iheezo, Flarex, Verkazia |
| Medline Industries LP | $54.40 | 2024-2025 | |
| Eyevance Pharmaceuticals LLC | $54.40 | 2019 | |
| Eyepoint US, INC. | $42.78 | 2019 | |
| Astellas Pharma US INC | $37.05 | 2025 | Izervay |
| Kala Pharmaceuticals, INC. | $31.49 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $25.32 | 2025 | Iluvien |
| Glaxosmithkline, LLC. | $25.08 | 2021 | |
| Apellis Pharmaceuticals, INC. | $24.99 | 2025 | Syfovre |
| Biotissue Holdings INC. | $23.02 | 2025 | |
| Halozyme INC | $17.21 | 2025 | Hylenex Recombinant |
| Regeneron Healthcare Solutions, INC. | $15.89 | 2025 | Eylea Hd |
| Shire North American Group INC | $15.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.